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Summary
INTRODUCTION: Left ventricular thrombus (LVT) form-
ation may worsen the post-infarct outcome as a result of
thromboembolic events. It also complicates the use of mod-
ern antiplatelet regimens, which are not compatible with
long-term oral anticoagulation. The knowledge of the in-
cidence of LVT may therefore be of importance to guide
antiplatelet and antithrombotic therapy after acute myocar-
dial infarction (AMI).
METHODS: In 177 patients with large, mainly anterior
AMI, standard cardiac magnetic resonance imaging (CMR)
including cine and late gadolinium enhancement (LGE)
imaging was performed shortly after AMI as per protocol.
CMR images were analysed at an independent core labor-
atory blinded to the clinical data. Transthoracic echocardio-
graphy (TTE) was not mandatory for the trial, but was per-
formed in 64% of the cases following standard of care. In a
logistic model, 3 out of 61 parameters were used in a mul-
tivariable model to predict LVT.
RESULTS: LVT was detected by use of CMR in 6.2%
(95% confidence interval [CI] 3.1%–10.8%). LGE se-
quences were best to detect LVT, which may be missed in
cine sequences. We identified body mass index (odds ratio
1.18; p = 0.01), baseline platelet count (odds ratio 1.01, p
= 0.01) and infarct size as assessed by use of CMR (odds
ratio 1.03, p = 0.02) as best predictors for LVT. The agree-
ment between TTE and CMR for the detection of LVT is
substantial (kappa = 0.70).
DISCUSSION: In the current analysis, the incidence of
LVT shortly after AMI is relatively low, even in a patient
population at high risk. An optimal modality for LVT de-
tection is LGE-CMR but TTE has an acceptable accuracy
when LGE-CMR is not available.
Key words: coronary thrombosis; myocardial infarction;
anticoagulants; magnetic resonance imaging
Introduction
Acute myocardial infarction (AMI) still represents a major
cause of mortality and morbidity [1]. Early mortality de-
creased dramatically because of widespread use of out clin-
ic automatic defibrillators, and improvement in acute car-
diac care leading to shorter times between first medical
contact and primary percutaneous coronary intervention
Figure 1
Left ventricular thrombus (4.03 cm3) in the short axis (A), vertical
long axis (B) and horizontal long axis (C) delayed enhancement
cardiac magnetic resonance imaging (DE-CMR) sequences. This
thrombus is as well detectable in the CMR-cine sequences, here
shown in the vertical axis (D).
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(PCI) [2]. Nevertheless, morbidity due to post-infarct com-
plications is still an important issue.
Among other factors, left ventricular thrombus (LVT)
formation may worsen the post-infarct outcome owing to
thromboembolic events [3, 4]. Most left ventricular (LV)
thrombi are “mural”, covering the left ventricular endocar-
dial wall with thrombotic material. In the prethrombolyt-
ic era, the incidence of LVT after AMI was reported to
lie between 17% [5] and 21% [6], with a peak incidence
in anterior-located infarcts of up to 46% [5], depending
mostly on infarct size. More recently, in the era of rapid
reperfusion therapy, the incidence of LVT markedly de-
creased to 6.2% [7], when assessed by use of transthoracic
echocardiography (TTE), and up to 8.8% [8], when entirely
assessed with late gadolinium enhancement (LGE) cardiac
magnetic resonance imaging (CMR). Although LVT with
only thin layers of thrombotic material may be difficult
to detect by looking at anatomical criteria (e.g. TTE; cine
CMR), tissue characterisation criteria (i.e. LGE-CMR) are
very powerful to detect these types of thrombi.
In the prethrombolytic and thrombolytic eras, prophylactic
long-term oral anticoagulation with a vitamin K antagonist
was often recommended [9–11] to prevent LVT formation.
To date, in the era of primary PCI and drug-eluting stents
(DES), the European guidelines [12] consider long-term
anticoagulation in the case of extensive, mainly anterior
AMI whereas they clearly recommend it exclusively in the
case of documented mural LVT.
Recent guidelines from the American Heart Association
[13], consider long-term anticoagulation therapy as a class
IIb indication for patients with a general risk of throm-
boembolic events, without, however, explicitly mentioning
LVT formation as a specific clinical situation.
This is of particular importance as combining oral antico-
agulation and double antiplatelet therapy (DAPT) into a
triple therapy increases bleeding risk and limits the choice
of newer P2Y12 inhibitors, such as prasugrel or ticagrelor,
which are prohibited in combination with vitamin K antag-
onists as well as to newer oral anticoagulants such as dabi-
gatran, rivaroxaban, edoxaban or apixaban [13].
Short-term anticoagulation regimens after AMI, on the oth-
er hand, are not precisely addressed in current guidelines
[12, 13]. In absence of data from randomised trials, it is not
clear if therapeutic parenteral anticoagulation using either
heparin or low molecular weight heparin (LMWH) directly
after primary PCI may efficiently prevent LVT formation
and for how long such therapy should be maintained.
Furthermore, patient- or infarct-related characteristics to
qualify for long-term oral anticoagulation to prevent LVT
formation are not well considered.
The aim of the present study is therefore three-fold: first,
to assess prospectively the incidence of mural LVT in a pa-
tient population that would be considered at risk for LVT
in accordance with current guidelines; second, to determine
the optimal imaging modality to detect reliably LV throm-
bus formation; and third; to look at patient- and infarct-re-
lated factors predisposing to mural LVT formation in the
modern era of primary PCI.
Methods
The present analysis is a substudy of the SWISS-AMI-trial
[14, 15]. This randomised, multicentre trial, aiming to test
the effect of intracoronary bone-marrow-derived mononuc-
lear cell (BM-MNC) administration, was performed in four
Swiss cardiovascular centres between 2006 and 2012, and
included a total of 200 patients, mainly with anterior AMI,
successfully reperfused by means of primary PCI and with
a left ventricular ejection fraction (LVEF) less than 45%.
As per protocol, all patients were studied with LGE-CMR
at baseline. The main inclusion criteria were a successful
primary PCI (or rescue PCI after initial thrombolysis) with-
in 24 hours after the onset of chest pain and a visual LVEF
equal or lower than 45%, as assessed by use of left
ventricular angiography the day of AMI or, alternatively,
with TTE the day following the AMI. The study was ap-
proved by the local ethics committee as well as by the com-
petent federal authorities.
Cardiac magnetic resonance imaging
CMR was performed at a median of 6 days (4 to 8) after the
AMI using 1.5-Tesla clinical MR system (Siemens Sonata
1.5 Tesla; Philips Achiever 1.5 Tesla) with a dedicated car-
diac phased-array receiver coil for signal reception, fol-
lowing a standard imaging protocol. It included cardiac
function (cine) and LGE imaging. Cine imaging of the LV
was performed by standard ECG-triggered steady-state free
precession sequence during repetitive breath-holds in three
long-axis orientations and in contiguous short-axis orient-
ation covering the entire LV. LGE imaging was performed
20 minutes after administration of a bolus of a conven-
tional extracellular gadolinium-chelates contrast medium
at a dose of 0.20 mmol per kilogram of bodyweight by
using an inversion-recovery (IR) fast gradient echo ima-
ging sequence [16–18]. After determination of the inver-
sion time nulling for normal myocardium, LGE imaging
was performed in identical locations to those where cine
Figure 2
Left ventricular thrombus (0.166 cm3) shown in the short axis (A),
vertical long axis (B) and horizontal long axis (C) delayed
enhancement cardiac magnetic resonance imaging (DE-CMR)
sequences. This thrombus is not detectable in the CMR-cine
sequences, here shown the vertical axis (D).
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data were acquired. CMR data analysis including research
for mural LVT was entirely performed in an experimented
core laboratory (University Hospital Zurich/CH) using a
dedicated cardiac analysis software (GTVolume, Gyrotools
Ltd, Zurich/CH). First, LV end-diastolic (LV-EDV) and
end-systolic (LV-ESV) volumes, LVEF and LV mass were
analysed. Scar mass and tissue with microvascular obstruc-
tion (MVO) were assessed in grams and as a percentage of
LV mass and of scar mass, respectively. The core laborat-
ory was completely blinded to all clinical data of the in-
cluded patients. They were blinded as to whether LVT was
found at TTE or not.
The presence or absence of LVT was assessed by analysing
visually LGE images (short axis, vertical long axis, hori-
zontal long axis) of each patient as well as by analysing
the corresponding cine sequences. LGE imaging has the
advantage over cine sequences in that gadolinium may
improve the contrast between thrombus and myocardium.
Furthermore, image quality is not compromised by ar-
rhythmias as images are acquired in end-systole. Thrombus
size was assessed by planimetry in short axis and vertical
long axis. Dedicated additional techniques, such as sequen-
tial infrared imaging and a long-inversion time, as de-
scribed later by Weinsaft [19] and co-workers, had not yet
been sufficiently studied when the trial started in 2006.
Transthoracic echocardiography
TTE was not part of the original study protocol. However,
it was often used for clinical purposes, particularly in order
to screen for eligibility for the SWISS AMI trial as one of
the key inclusion criteria was a visual LVEF of <45%. Of
note, no study-specific protocol was applied; assessment of
LV function and the research for mural LVT was performed
according to the routine protocol of the participating centre,
and the use of contrast medium was neither encouraged nor
prohibited. In 15 patients (13.2%) it was effectively utilised
to evaluate the absence or presence of LVT. Operators or
readers of TTE were not blinded to the results of CMR per
protocol; however, in only a minority of cases (14 out of
113) were CMR results available at the time of TTE.
Statistical analysis
Descriptive statistics of continuous variables are presented
as mean and standard deviation or median and 25th and
75th percentiles, if skewed. Nominal variables are summar-
ised in terms of frequencies and percentages.
The agreement between echo and the reference test CMR
to identify thrombi was assessed with the kappa statistic.
Also, sensitivity, specificity and predictive values (with
95% confidence intervals [CI]) were computed [20].
Predictors of LVT at CMR were assessed by means of
either logistic regression or exact logistic regression mod-
els; odds ratios (OR) and 95% CIs were computed for 61
parameters in a univariable analysis. Multivariable model-
ling was limited by the low number of patients with LVT;
for this reason we only included the best predictor among
each of cardiovascular risk factors, biomarkers and CMR-
or infarct-related parameters. The receiver operating char-
acteristic (ROC) area und the curve were computed for
each model to measure discrimination and the shrinkage
coefficient to measure overfitting (for both, the closer to 1,
the better) [21].
Continuous variables with skewed distribution were log
transformed. All p-values are two–sided and values ≤0.05
are considered significant. Stata 13 (StataCorp, College
Station, TX, USA) was used for computation.
Results
A total of 200 patients were included in the SWISS AMI
study between October 2006 and January 2012 in four
Swiss participating centres. Excluding early drop-outs and
other cases in which for some reason no CMR has been
performed at baseline, 177 patients were included in the
present study. In 113 cases (63.8%), besides baseline CMR
imaging, TTE was also performed in the first days after
AMI.
The patients’ mean age was 56.8 (10.2) years and 85%
were of male gender. Overall, 93% of the patients had an-
terior ST-elevation myocardial infarction (STEMI) due to
occlusion of the left anterior descending coronary artery,
and the time from onset of chest pain to reperfusion therapy
was 6.5 (5.8) hours. Overall, 77% of the patients were
treated with glycoprotein IIb/IIIa inhibitors or bivalirudin
and 77% received a DES with a mean diameter of 3.3 (0.3)
mm. Maximal creatine kinase (CK) plasma levels were
4,291 (2,499) U/l, and baseline LVEF, as assessed by CMR
was 37.7% (9.5%).
The entire recorded patient characteristics are shown in
table 1.
Thrombus detection
A total of 11 (prevalence: 6.2%, 95% CI 3.1%–10.8%)
mural LV thrombi were detected, with a mean volume of
4.1 (4.3) cm3 (table 2). Although all thrombi were detec-
ted in the short axis and vertical long axis of the LGE se-
quences, in two cases with a small thrombus burden (<1
cm3), LVT was not seen in the horizontal long axis of the
LGE sequences. LVT was more frequently missed in the
cine sequences: in three cases, owing to a small volume
(<0.5 cm3), LVT was not detectable at all and in two cases
even larger LV thrombi were detected in only one out of
three cine sequences.
TTE was performed in 113 (63.8%) of the included patients
within the first days after AMI. It was available in 10 of
the 11 LVT cases and was performed at a median of 1 day
(–0.75 to 2.5 days) after CMR. In two cases LVT was not
visible at TTE. In one case this may be explained by the
small size of the LVT (0.43 cm3) but in the second case
the missed LVT was the largest of all detected LV thrombi
(14.3 cm3). In four cases TTE images were positive or sus-
picious for LVT, without confirmation by CMR. Of note,
the TTE positive for LVT were performed in all cases be-
fore CMR (5 days, 2 days, 1 day and 1 day earlier) and
subsequent CMR imaging was therefore performed under
full anticoagulation therapy, which was immediately star-
ted after receiving the TTE results or maintained if already/
still active. Contrast medium (CM) was used in 15 patients
(13.3%). In 10 patients the use of CM permitted LVT to
be ruled out, which was confirmed by CMR in all cases.
Among the five patients who were tested “positive” for
Original article Swiss Med Wkly. 2015;145:w14122
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Table 1: Baseline patient characteristics.
CMR
(n = 177)
CMR and TTE
(n = 113)
Age – years 56.8 (10.2) 56.0 (9.6)
BMI – kg/m2 27.3 (3.9) 27.3 (3.6)
Male gender – % 85.3 87.6
Hypertension – % 42.1 40.2
Hyperlipidemia – % 41.5 43.7
Diabetes – % 10.8 8.9
Smoking (active/previous) – % 58.5 64.3
Family history of CAD – % 30.1 33.9
1 / 2 / 3 vessel disease – % 57.9 / 27.3 / 14.8 59.8 / 27.7 / 12.5
Previous PCI before AMI – % 2.3 3.6
Infarct treatment and parameters
Primary PCI – % 97.2 97.3
Concomitant PCI other than infarct related artery – % 14.3 16.2
Infarct vessel LAD / LCX / RCA – % 93.2 / 2.3 / 4.5 95.5 / 0.9 / 3.6
Pain to revascularization time – h * 4.51 (2.75–8.00) 4.00 (2.75–7.25)
Stent diameter – mm 3.27 (0.34) 3.26 (0.34)
Drug eluting stent – % 77.4 73.5
TIMI 0 flow before PCI – % 89.6 86.2
TIMI 3 flow after PCI – % 94.2 92.7
Use of GP IIb/IIIa inhib. / bivalirudin – % 76.7 78.6
Maximal creatine kinase – U/l* 3891 (2206–5805) 4280 (2598–6169)
Maximal creatine kinase-MB – U/l 305 (191–493) 327 (185–489)
Baseline NT-proBNP – ng/l 1421 (811–2555) 1678 (877–2605)
Total cholesterol – mmol/l 4.56 (1.27) 4.64 (1.24)
LDL-cholesterol – mmol/l 2.85 (1.19) 2.92 (1.17)
Creatinine – mmol/l 83.4 (19.7) 81.9 (16.2)
CRP – mg/l 6.9 (3–24) 11 (4–26)
ASAT – U/l 60 (34–155) 66 (34–180)
LDH – U/l 773 (455–1274) 863 (559–1478)
WBC – (x109/l) 9.83 (3.94) 9.8 (4.2)
Haemoglobin – g/dl 13.72 (1.70) 13.7 (1.8)
Haematocrit – % 39.75 (4.73) 39.7 (4.9)
Platelets – (x109/l) 263.1 (80.1) 270.3 (82.8)
Infarct treatment at CMR
Infarct size – g 42.6 (24.5) 45.4 (26.1)
% infarction 28.5 (12.2) 29.2 (12.9)
Microvascular obstruction – g 0.64 (0–2.69) 0.92 (0–3.77)
LVEDV – ml 154.7 (38.1) 160.4 (38.8)
LVESV – ml 97.6 (32.6) 103.9 (34.1)
LVEF – % 37.7 (9.5) 36.0 (9.4)
Medication before AMI – %
Aspirin 5.1 5.4
Clopidogrel 1.1 1.8
ACE-inihibitor 6.3 5.4
ATII receptor blocker 8.6 8.9
Beta-blocker 5.1 3.6
Diuretic 3.4 3.6
Statin 5.7 6.2
Oral antidiabetic drug 4.0 5.4
Medication at discharge – %
Aspirin 98.3 97.3
Clopidogrel 69.1 66.1
Prasugrel 30.9 33.9
ACE-inihibitor 88.6 85.7
ATII receptor blocker 8.6 8.9
Beta-blocker 90.3 91.1
Diuretic 30.3 33.9
Statin 98.9 99.1
Oral antidiabetic drug 6.3 7.1
Original article Swiss Med Wkly. 2015;145:w14122
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ACE = angiotensin converting-enzyme; AMI = acute myocardial infarction; ASAT = aspartate aminotransferase; ATII = angiotensin II receptor; BMI = body mass index;
CAD = coronary artery disease; CMR = cardiac magnetic resonance imaging; CRP = C-reactive protein; LAD = left anterior descending artery; LCX = left circumflex artery;
LDH = lactate dehydrogenase; LDL = low-density lipoprotein; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left
ventricular end-systolic volume; NT-proBNP = N-terminal of prohormone brain natriuretic peptide; PCI = percutaneous coronary intervention RCA = right coronary artery;
TTE = transthoracic echocardiography; WBC = white blood cell count;
Continuous variables are presented as mean and standard deviation, or (*) median and 25th–75th percentiles if skewed. Nominal variables are summarised in terms of
percentages.
LVT by TTE using CM, this was, confirmed only in two
cases.
Whether CM was used or not, the diagnostic value of TTE
was fairly good (supplemental table), with an area under
the ROC curve of 0.88 (95% CI 0.75–1), a sensitivity of
80% (95% CI 44.4%–97.5%) and a specificity of 96.1%
(95% CI 90.4%–98.9%). The agreement between TTE and
CMR for the detection of LVT is substantial (kappa statistic
= 0.70; 7.1% positive agreement, 86.1% negative agree-
ment).
Predictors for LVT formation
Searching for predictors of LVT, a total of 61 parameters
have been addressed in a univariable analysis (table 3). In
a logistic model we identified BMI (odds ratio 1.18; p =
0.01), baseline platelet count (odds ratio 1.01, p = 0.01) and
infarct size as assessed by CMR (odds ratio 1.03, p = 0.02)
as best predictors for LVT. Taken together in a multivari-
able model, these three parameters solidly describe the risk
of LVT formation (chi-square –26.63, p = 0.002), with a
good discrimination ability (area under the ROC curve =
0.83) and little overfitting (shrinkage 0.80).
Clinical events
As defined in the study protocol, the incidence of stroke
(and other clinical events such as death, myocardial infarc-
tion or coronary revascularisation) has been assessed in all
included patients. The 11 patients with documented throm-
bus formation were entirely treated with oral anticoagula-
tion on top of DAPT in addition to therapeutic LWMH or
unfractionated heparin until a therapeutic INR (between 2
and 3) was reached. No stroke has been reported in the first
4 months, whereas 2 (0.6%) strokes occurred in the patients
without documented LVT formation.
Discussion
Prevention, detection and management of mural LVT after
AMI is challenging and has often been a matter of dis-
cussion [20]. Most of the evidence concerning mural LVT
formation derives from studies of the pre-fibrinolysis and
fibrinolysis eras. Currently, American and European
guidelines for the management of STEMI [12, 13] do not
precisely consider the length of therapeutic anticoagulation
with unfractionated heparin or LMWH after primary PCI.
According to guidelines, triple therapy with a vitamin K
antagonist (up to 3 months), aspirin, and a P2Y12 receptor
inhibitor after STEMI should be restricted to specific clin-
ical situations in which the risk of systemic thromboem-
bolism is considered to exceed that of bleeding. It is, fur-
thermore, recommended to consider patient preferences, as
patients may weigh these outcomes differently [13]. As
risk factors for LVT, guidelines mention antero-apical akin-
esia or dyskinesia without specifying the imaging modality
used to look for this and the optimal time point to consider
LVT formation after AMI.
In the current study, most of the patients would have been
considered at risk for LVT in accordance with guidelines
as they had large, mainly anterior infarction with a mean
Supplementary table: Sensitivity, specificity and predictive values of
TTE, compared to CMR.
Thrombus at TTE
Thrombus at
CMR
Absence Presence Total
Presence 2 (1.8%) 8 (7.1%) 10
Absence 99 (87.6%) 4 (3.5%) 103
Total 101 12 113
Kappa = 0.70 (substantial agreement); sensitivity = 80% (95% CI
44%–97%); specificity = 96.1% (95% CI 90%–99%); positive
predictive value = 66.7% (95% CI 35%–90%); negative predictive
value = 98% (95% CI 93%–100%) with 8.8% prevalence
CI = confidence interval
Table 2: Characteristics of the left ventricular thrombi and left ventricular thrombus detection.
Thrombus LE-CMR sequences CMR-cine sequences
No. Dimension (cm3) sax vla hla 3D sax vla hla
TTE Time delay
1 0.166 + + + ND – – – ND ND
2 5.724 + + + ND + + + + * –1
3 4.836 + + + + + + + + –15
4 5.062 + + + ND + + + + 1
5 2.188 + + + + – – + + 1
6 14.3 + + + ND + + + – 3
7 4.03 + + + + + + + + * –1
8 0.027 + + – + – – – + 10
9 0.427 + + + + – – – – 6
10 0.768 + + – + + – – + –2
11 8.067 + + + + + + + + 0
3D = three dimensional; CMR = cardiac magnetic resonance imaging; hla: horizontal long axis; LE = late enhancement; ND = not done; No. = number; sax = short axis; vla
= vertical long axis; TTE: trans-thoracic echocardiography
Time delay is the time delay between TTE and CMR (if positive TTE before CMR, if negative TTE after CMR).
* TTE was also performed using contrast medium.
Original article Swiss Med Wkly. 2015;145:w14122
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Table 3: Predictors of LVT formation.
Presence of Thrombus Absence of Thrombus OR (95%CI) p
Gender – no (%)
Male 10 (6.6) 141 (93.3) –
Female 1 (3.8) 25 (96.2) 0.56 (0.01–4.30)
0.71
Infarct vessel – no (%)
LAD 11 (6.7) 153 (93.3) –
LCX 0 4 (100) 2.71 (0–23.2)
RCA 0 8 (100) 1.30 (0–9.36)
0.74
Coronary artery disease – no (%)
1 vessel disease 9 (8.8) 93 (91.2) –
2 vessel disease 2 (4.2) 46 (95.8) 0.45 (0.05–2.3)
3 vessel disease 0 26 (100) 0.29 (0–1.96)
0.18
Previous PCI before AMI 1 (25) 3 (75) 5.30 (0.09–73.34)
No previous PCI before AMI 10 (5.8) 162 (94.2) –
0.23
Infarct treatment and circumstances of AMI – no (%)
Primary PCI 11 (6.4) 161 (93.6) –
Thrombolysis 0 5 (100) 2.2 (0–17.9)
1.00
Concomitant PCI other than infarct related artery 1 (4) 24 (96) –
No Concomitant PCI other than infarct related artery 10 (6.7) 140 (93.3) 0.58 (0.01–4.46)
0.71
TIMI flow before PCI = 0 8 (5.2) 147 (94.8) –
TIMI flow before PCI = 1 1 (7.7) 12 (92.3) 1.53 (0.32–13.17)
TIMI flow before PCI = 2 0 4 (100) 3.61 (0–31.87)
TIMI flow before PCI = 3 0 1 (100) 18.5 (0–721)
1.00
TIMI flow after PCI = 2 1 (10) 9 (90) –
TIMI flow after PCI = 3 8 (4.9) 155 (95.1) 0.47 (0.52–22.87)
1.00
Use of Glycoprotein IIb/IIIa
Inhibitors / bivalirudin
8 127 –
No use of Glycoprotein
Ib/IIIa Inhibitors / bivalirudin
3 (7.3) 38 (92.7) 0.80 (0.18–4.90)
1.00
Early heart failure after AMI 4 (13.8) 25 (86.2) –
No heart failure after AMI 7 (4.8) 140 (95.2) 3.17 (0.63–13.60)
0.09
Initial VF during AMI 3 (9.1) 30 (90.9) –
No VF during AMI 8 (5.6) 135 (94.4) 1.68 (0.27–7.55)
0.69
Time from initial chest pain to revascularization (h) – * 4.4 (3.0–18.0) 4.5 (2.7–77) 1.56 (0.66–3.67) 0.32
Cardiovascular risk factors – no (%)
Arterial hypertension 6 (8.1) 68 (91.9) –
No Arterial hypertension 5 (4.9) 97 (95.1) 1.71 (0.42–7.37
0.53
Hyperlipidemia 6 (8.2) 67 (91.8) –
No Hyperlipidemia 5 (4.8) 98 (95.1) 1.75 (0.42–7.56)
0.53
Familiar history for CVD 3 (5.7) 50 (94.3) –
No Familiar history for CVD 8 (6.5) 115 (93.5) 0.86 (0.14–3.79)
1.00
Smoking (former or active) 8 (7.8) 95 (92.2) –
No smoking (former or active) 3 (4.1) 70 (95.9) 1.96 (0.45–11.87)
0.37
Diabetes mellitus 3 (15.8) 16 (84.2) –
No diabetes mellitus 8 (5.1) 149 (94.9) 3.46 (0.54–16.38)
0.10
BMI – mean (SD) 30.4 (5.3) 27.1 (3.7) 1.18 (1.04–1.34) 0.01
Age (years) – mean (SD) 57.0 (8.5) 56.8 (10.3) 1.00 (0.94–1.06) 0.95
Baseline biological markers – mean (SD) or *median (25th-75th)
Maximal CK – U/l* 4363 (1815–6480) 3882 (2212–5794) 0.96 (0.39–2.41) 0.93
Maximal CK-MB – U/l* 493 (218–660) 301 (184–489) 1.86 (0.78–4.45) 0.14
nt-pro BNP – ng/l* 2350 (1661–3002) 1325 811-2496) 1.26 (0.54–2.94) 0.58
Hemoglobin – g/dl 14.1 (1.2) 13.7 (1.7) 1.16 (0.77–1.76) 0.47
Hematocrite – % 40.5 (4.2) 39.7 (4.8) 1.04 (0.90–1.20) 0.60
Platelets – [x109/l] 334 (108) 258 (76) 1.01 (1.00–1.02) 0.01
Creatinine – mcmol/l 88.9 (26.3) 83.1 (19.4) 1.01 (0.98–1.05) 0.44
White blood cells – [x109/l]* 12.8 (10–14.1) 8.7 (6.6–12.2) 5.81 (0.84–40.46) 0.07
C-reactice protein – mg/l* 9.5 (4–24) 6.85 (3–24) 1.04 (0.63–1.72) 0.89
CMR characteristics of the LV – mean (SD) or *median (25th–75th)
Delay between AMI and CMR – days* 8 (4–10) 6 (4–8) 2.00 (0.58–6.91) 0.27
LVEF – % 35.2 (6.3) 37.8 (9.7) 0.97 (0.91–1.04) 0.36
LVEDV – ml 174 (24) 153 (39) 1.01 (1.00–1.03) 0.10
LVESV – ml 113 (22) 97 (33) 1.01 (1.00–1.03) 0.12
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Infarct size – g 60.0 (23.7) 41.4 (24.2) 1.03 (1.00–1.05) 0.02
Myocardial scar – % 34.0 (9.5) 28.1 (12.3) 1.04 (0.99–1.09) 0.13
LV mass diastolic 147 (36) 124 (41) 1.01 (1.00–1.03) 0.08
Presence of MVO – no (%) 6 (6.1) 92 (93.9) –
Absence of MVO – no (%) 3 (5.2) 55 (94.8) 1.19 (0.24–7.68)
1.00
Medication before AMI – no (%)
Aspirin 1 (11.1) 8 (88.9) –
No Aspirin 10 (6.0) 156 (94.0) 1.94 (0.40–17.22)
1.00
Clopidogrel 0 2 (100) –
No Clopidogrel 11 (6.4) 162 (93.6) 6.22 (0–82.33)
1.00
ACE-inhibitor 0 11 (100) –
No ACE-inhibitor 11 (6.7) 153 (93.3) 0.94 (0–6.45)
0.63
ATII receptor blocker 0 15 (100) –
No ATII receptor blocker 11 (6.9) 149 (93.1) 0.7 (0–4.44)
0.60
Beta-blocker 0 9 (100) –
No Beta-blocker 11 (6.6) 155 (93.4) 1.17 (0-8.24)
0.65
Statin 0 10 (100) –
No statin 11 (6.7) 154 (93.3) 1.04 (0–7.24)
0.64
Medication acutely after AMI – no (%)
Aspirin 11 (6.4) 161 (93.6) –
No Aspirin 0 3 (100) 0.26 (0.03–Inf)
1.00
Clopidogrel 8 (6.6) 113 (93.4) –
No Clopidogrel 3 (5.6) 51 (94.4) 1.20 (0.27–7.32)
1.00
Prasugrel 3 (5.6) 51 (94.4) –
No Prasugrel 8 (6.6) 113 (93.4) 0.83 (0.14–3.65)
1.00
Continuous variables are presented as mean and standard deviation or (*) median and 25th–75th percentiles, if skewed and log-transformed for regression analysis.
Nominal variables are summarized in terms of percentages.
Abbreviations: OR: odds ration; LAD: left anterior descending coronary artery; LCX: left circumflex artery; RCA right coronary artery; PCI: Percutaneous coronary
intervention; AMI: acute myocardial infarction; TIMI: Thrombolysis in Myocardial Infarction; VF: ventricular fibrillation; h: hours; CVD: cardiovascular disease; BMI: body
mass index; CK: creatine kinase; CK-MB: creatine kinase – muscle brain; nt-pro BNP: nt-pro terminal brain natriuretic peptide; LVEF: left ventricular ejection fraction;
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; MVO: microvascular obstruction; ACE: angiotensin-converting–enzyme; AT:
angiotensin.
LVEF of 37.4%. Nevertheless, the incidence of LVT in
our study (6.2%) did not differ much from a recently pub-
lished similar series [7, 8], which reported an incidence of
6.2%–8.8%. Best predictors for LVT formation are a high-
er BMI, elevated platelet counts and a large scar size on
CMR.
The potential predictive value of large infarct size on LVT
formation appears logical and has already been described
by others [8, 19]. Obesity, expressed as elevated BMI, has
also been discussed as a potential predictor for a higher in-
cidence of left atrial thrombus in patients with atrial fibril-
lation [21]. Among the possible explanations for this phe-
nomenon are high fibrinogen levels [22] as well as chronic
inflammation directly promoted by excretion of proinflam-
matory proteins from the adipose tissue [23] leading to pro-
thrombosis [24, 25]. The precise mechanism of the effect
of obesity on LVT formation remains unclear.
A higher platelet count is commonly known to be a risk
factor for intravascular thrombus formation [28]; however,
it has never been shown to be associated with LVT forma-
tion after AMI.
As for the protocol of the original SWISS AMI study, all
patients underwent CMR, according to a standard protocol
including LGE imaging, within a median of 6 days (4–8)
after AMI. This technique robustly detects LVT [8], even
without dedicated additional techniques, such as sequential
infrared imaging and a long inversion time, as described
later by Weinsaft [19] and co-workers in 2006, when the
current trial was already started. Similar to the results of
earlier studies [8, 19], our data confirm that LVT may be
missed with TTE and even CMR with cine imaging only.
This underscores the impact of LGE-CMR in the early
management of AMI.
Given the low incidence of LVT in this patient population
at high risk for LVT, the potential risk of systematic pro-
phylactic long-term oral anticoagulation combined with
DAPT may outweigh the potential benefit as it clearly in-
creases the risk of bleeding [29, 30] and as it is, further-
more, not compatible with modern antiplatelet regimens
including prasugrel or ticagrelor. It should, therefore, be
considered only in patients with clearly documented LVT,
at best by use of LGE-CMR. Whether prophylactic long-
term oral anticoagulation might be indicated in special situ-
ations or with patients characteristics indicating risk (i.e. in
the case of elevated BMI, higher platelet counts and large
infarct size) cannot be answered by the present study. Pro-
spective, randomised controlled trials (such as Piek J et al.;
Clinical trials.gov id:NCT01556659) comparing in a ran-
domised manner DAPT with or without additional oral an-
ticoagulation may be helpful in the future.
Study limitations
First, when starting the study, our knowledge of dedicated
CMR sequences to detect LVT were limited as alternative
sequences [19] were published later.
Second, the original trial was not designed to evaluate the
incidence of LVT formation, nor to address the sensitivity
and specificity of TTE to detect LVT, as CMR and TTE
were generally not performed on the same day and TTE
was performed “out of protocol”. Therefore, the possibil-
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ity that the time delay between the two examinations may
be responsible for false negative or false positive results
cannot be completely excluded. Especially given the high-
er sensitivity of TTE to detect LVT (sensitivity = 80%) in
our study compared with earlier results [8, 31].
Third, the long duration between enrolment of the first and
the last patients may lead to imbalances in the manage-
ment of STEMI, as during the study period new antiplatelet
agents were introduced (such as bivalirudin and prasugrel).
Fourth, in the original study protocol the length and the
type of therapeutic anticoagulation regimen was not spe-
cifically defined.
Fifth, because of the large number of statistical tests (par-
ticularly the search for predictors for LVT out of 61 para-
meters), there may be an increased overall probability of a
type I error. Thus, the results of this study have to be there-
fore strictly considered as “hypothesis generating”.
In conclusion, the incidence of mural LVT shortly after
AMI is relatively low, even in a patient population, which
may be considered at higher risk for thrombus formation,
which may be actually explained by the rapid access to
and the constant improvement in revascularisation tech-
niques for patients with AMI. Nevertheless, a systematic
research of LVT shall be considered in all patients after
AMI. An optimal modality for LVT detection is LGE-
CMR but echocardiography has an acceptable sensitivity
and specificity when CMR is not available. If for a sub-
group of patients with high BMI and large scar size and
high platelet levels, prophylactic long-term anticoagulation
may be indicated, remains unclear.
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Figures (large format)
Figure 1
Left ventricular thrombus (4.03 cm3) in the short axis (A), vertical long axis (B) and horizontal long axis (C) delayed enhancement cardiac
magnetic resonance imaging (DE-CMR) sequences. This thrombus is as well detectable in the CMR-cine sequences, here shown in the vertical
axis (D).
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Figure 2
Left ventricular thrombus (0.166 cm3) shown in the short axis (A), vertical long axis (B) and horizontal long axis (C) delayed enhancement
cardiac magnetic resonance imaging (DE-CMR) sequences. This thrombus is not detectable in the CMR-cine sequences, here shown the
vertical axis (D).
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